Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8870175 | 0.79 | IDO1 (0.57) | IDO1MTNR1ACYP2A6CA1CA2 | |
| SCHEMBL25029541 | 0.79 | IDO1 (0.54) | IDO1MTNR1ACYP2A6CA1CA2 | |
| SCHEMBL6973697 | 0.78 | IDO1 (0.60) | IDO1MTNR1ACYP2A6CA1CA2 | |
| SCHEMBL31370245 | 0.77 | MTNR1A (0.55) | IDO1MTNR1ACYP2A6CA1CA2 | |
| SCHEMBL4332333 | 0.76 | MTNR1A (0.65) | IDO1MTNR1ACYP2A6CA1CA2 | |
| SCHEMBL761159 | 0.75 | NQO2 (0.57) | IDO1MTNR1ACYP2A6CA1CA2 | |
| SCHEMBL760833 | 0.75 | MTNR1A (0.67) | IDO1MTNR1ACYP2A6TAAR1SMN1; SMN2 | |
| SCHEMBL8763407 | 0.74 | ADH1B (0.46) | MTNR1ACA2CA12CA9TAAR1 | |
| SCHEMBL25029860 | 0.74 | IDO1 (0.56) | IDO1MTNR1ACYP2A6CA1CA2 | |
| SCHEMBL1445363 | 0.74 | CYP2A6 (0.60) | CYP2A6CA1CA2CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138218-B2 | Growth hormone secretagogues | IPSEN PHARMA S.A.S. (FR) | 2012-03-20 | — | — | US | disclosed |
| US-20090131478-A1 | Growth Hormone Secretagogues | IPSEN PHARMA S.A.S. (FR) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131478-A1 | Growth Hormone Secretagogues | GHSR, GHRHR, GHITM | IDO1 3416/4885MTNR1A 478/4885CYP2A6 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.